
...BIBLIOGRAPHY...

- Anderson S, Rennke HG, Brenner BM. Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat. *J Clin Invest* 1986;77:1993-2000.
- Apperloo AJ, de Zeeuw D, de Jong PE. A short-term anti-hypertensive-treatment induced drop in glomerular filtration rate predicts long-term stability of renal function. *Kidney Inter* 1997;51:793-797.
- Azizi M, Rousseau A, Ezan E, et al. Acute angiotensin-converting enzyme inhibition increases the plasma levels of the natural stem cell regulator N-acetyl-seryl-aspartyl-lysyl-proline. *J Clin Invest* 1996;97:839-844.
- Bastani B, Redington J. Lack of efficacy of angiotensin converting enzyme inhibitors in reducing interdialytic weight gain. *Am J Kidney Dis* 1994;24:907-911.
- Berk BC, Alexander RW. Biology of the vascular wall in hypertension. In: Brenner B, ed. *The Kidney* 5th ed. Philadelphia, PA: WB Saunders Company;1996:2049-2070.
- Beto JA, Bansal VK. Quality of life in treatment of hypertension. A metaanalysis of clinical trials. *Am J Hypertens* 1992;5:125-133.
- Bigazzi R, Bianchi S, Baldari G, et al. Clustering of cardiovascular risk factors in salt-sensitive patients with essential hypertension: Risk of insulin. *Am J Hypertens* 1996;9:24-32.
- Blumenthal JA, Ekelund LG, Emery CF. Quality of life among hypertensive patients with a diuretic background who are taking atenolol and enalapril. *Clin Pharmacol Ther* 1990;48(4):447-454.
- Bootman JL, Townsend RJ, McGhan WF. *Principles of Pharmacoeconomics*. Cincinnati, OH: Harvey Whitney Books, 1996.
- Borch-Johnsen K. ACE inhibitors in patients with diabetes mellitus. Clinical and economic considerations. *Pharmacoeconomics* 1996;9(5):392-398.
- Briscoe TA, Dearing CJ. Clinical and economic effects of replacing enalapril with benazepril in hypertensive patients. *Am J Health Syst Pharm* 1996;53:2191-2193.
- Brunner HR, Waeber B, Nussberger J. Angiotensin-converting enzyme inhibitors. In: Messerli F, ed. *Cardiovascular Drug Therapy* 2nd ed. Philadelphia, PA: WB Saunders, 1996:690-711.
- Brunner HR, Waeber B, Nussberger J. Does pharmacological profiling of a new drug in normotensive volunteers provide a useful guide to antihypertensive therapy? *Hypertension* 1983;5(suppl III):101-107.
- Bulpitt CJ, Beevers DG, Butler A, et al. The survival of treated hypertensive patients and their causes of death: A report from the DHSS hypertensive care computing project (DHCCP). *J Hypertens* 1986;4(1):93-99.
- Bulpitt CJ, Fletcher AE. Importance of well-being to hypertensive patients. *Am J Med* 1988;84(1B):40-46.
- Bulpitt CJ, Fletcher AE. Quality of life evaluation of anti-hypertensive drugs. *Pharmacoeconomics* 1992;1(2):95-102.
- Burt VL, Cutler JA, Higgins M, et al. Trends in prevalence, awareness, treatment, and control of hypertension in the adult U.S. population. Data from the Health Examination Surveys, 1960-1991. *Hypertension* 1995;26:60-69.
- Butler JR, Fletcher PJ. A cost-effectiveness analysis of enalapril maleate in the management of congestive heart failure in Australia. *Aust N Z J Med* 1996;26(1):89-95.
- Caro JJ, Speckman JL, Salas M, et al. Effect of initial drug choice on persistence with antihypertensive therapy: The importance of actual practice data. *Can Med Assoc J* 1999;160:41-46.
- Case DB, Atlas SA, Laragh JH, et al. Use of first dose response or plasma renin activity to predict the long-term effect of captopril: Identification of triphasic pattern of blood pressure response. *J Cardiovasc Pharmacol* 1980;2:339-346.
- Chalmers D, Dombey SL, Lawson DH. Post-marketing surveillance of captopril (for hypertension). *Br J Clin Pharmacol* 1987;24:343-349.
- Cheng A, Frishman WH. Use of angiotensin-converting enzyme inhibitors as monotherapy and in combination with diuretics and calcium channel blockers. *J Clin Pharmacol* 1998;38:477-491.
- Chrysant SG. Vascular remodeling: The role of angiotensin converting enzyme inhibitors. *Am Heart J* 1998;135(suppl):S21-S30.
- Cody R. Optimizing angiotensin-converting enzyme inhibitor therapy of congestive heart failure: Insights from pharmacodynamic studies. *Clin Pharmacokinet* 1993;24:59-70.

... BIBLIOGRAPHY ...

- Cohn JN, Johnson G, Ziesche S, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure [see comments]. *N Engl J Med* 1991;325(5):303-310.
- Correa FJ, Eiser AR. Angiotensin-converting enzyme inhibitors and lithium toxicity. *Amer J Med* 1992;93:108-109.
- Croog SH, Levine S, Testa MA, et al. The effects of anti-hypertensive therapy on the quality of life. *N Engl J Med* 1986;314(26):1657-1664.
- Daly P, Mettauer B, Rouleau JL, et al. Lack of reflex increase in myocardial sympathetic tone after captopril: Potential antianginal mechanism. *Circulation* 1985;71:317-325.
- DeFronzo R, Ferrannini E. Insulin resistance: A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic disease. *Diabetes Care* 1991;14:173-194.
- Domanski MJ, Exner DV, Borkowf CB, Geller NL, Rosenberg Y, Pfeffer MA. Effect of angiotensin converting enzyme inhibition on sudden cardiac death in patients following acute myocardial infarction. A meta-analysis of randomized clinical trials. *J Am Coll Cardiol* 1999;33(3):598-604.
- Doyle JC, Mottram DR, Stubbs H. Prescribing of ACEIs for cardiovascular disorders in general practice. *J Clin Pharm Ther* 1998;23:133-136.
- Drexler H. Endothelial dysfunction: Clinical implications. *Prog Cardiovasc Dis* 1997;39:287-324.
- Drummond MF, O'Brien B, Stoddart GL, Torrance GW. *Methods for the Economic Evaluation of Health Care Programs*. Oxford: Oxford University Press, 1997.
- Eccles M, Freemantle N, Mason J. North of England evidence based development project: Guideline for angiotensin converting enzyme inhibitors in primary care management of adults with symptomatic heart failure [see comments]. *Br Med J* 1998;316:1369-1375.
- Edelson JT, Weinstein MC, Tosteson AN, Williams L, Lee TH, Goldman L. Long-term cost-effectiveness of various initial monotherapies for mild to moderate hypertension [see comments]. *JAMA* 1990;263(3):407-413.
- Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators [see comments]. *Lancet* 1993;342:821-828.
- Fagard R, Amery A, Reybrouck T, et al. Acute and chronic systemic and hemodynamic effects of angiotensin converting enzyme inhibition with captopril in hypertensive patients. *Am J Cardiol* 1980;46:295-300.
- Finnerty FA Jr. Stepped-down therapy versus intermittent therapy in systemic hypertension. *Am J Cardiol* 1990;66:1373-1374.
- Fourth International Study of Infarct Survival, Collaborative Group (ISIS-4): A randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. *Lancet* 1995;345:669-685.
- Frei A, Muller-Brand J. Cerebral blood flow and antihypertensive treatment with enalapril. *J Hypertens* 1986;4:365-368.
- Gainer JV, Morrow JD, Loveland A, et al. Effect of bradykinin-receptor blockade on the response to angiotensin-converting enzyme inhibitor in normotensive and hypertensive subjects. *N Engl J Med* 1998;339:1285-1292.
- Gansevoort RT, de Zeeuw D, de Jong PE. Additive antiproteinuric effect of ACE inhibition and a low protein diet in human renal disease. *Nephrol Dial Transplant* 1995;10:497-504.
- Garattini L, Brunetti M, Salvioni F, Barosi M. Economic evaluation of ACE inhibitor treatment of nephropathy in patients with insulin-dependent diabetes mellitus in Italy. *Pharmacoeconomics* 1997;12(1):67-75.
- Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials [published erratum appears in *JAMA* 1995;274(6):462] [see comments]. *JAMA* 1995;273(18):1450-1456.
- Gavras I. Bradykinin-mediated effects of ACE inhibition. *Kidney Int* 1992;42:1020-1029.
- Gerbrandt KR, Yedinak KC. Formulary management of ACE inhibitors. *Pharmacoeconomics* 1996;10(6):594-613.
- Giatras I, Lau J, Levey SS. Effect of angiotensin converting enzyme inhibitors on the progression of nondiabetic renal disease: A meta-analysis of randomized trials. *Ann Intern Med* 1997;127:337-345.

... BIBLIOGRAPHY ...

- Glick H, Cook J, Kinosian B. Costs and effects of enalapril therapy in patients with symptomatic heart failure: An economic analysis of the studies of left ventricular dysfunction (SOLVD) treatment trial. *J Card Failure* 1995;1:371-379.
- Gradman AH, Cutler NR, Davis PJ, et al. Combined enalapril and felodipine extended release for systemic hypertension. Enalapril-Felodipine ER Factorial Study Group. *Am J Cardiol* 1997;79:431-435.
- Gruppo Italiano per lo Studio della Sopravvivenza nell'infarto Miocardico (GISSI-3). Effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. [see comments]. *Lancet* 1994;343:1115-1122.
- Guazzi MD, Campodonico J, Celeste F, et al. Antihypertensive efficacy of angiotensin converting enzyme inhibition and aspirin counteraction. *Clin Pharmacol Ther* 1998;63:79-86.
- Hall AS, Murray GD, Ball SG. Follow-up study of patients randomly allocated ramipril or placebo for heart failure after acute myocardial infarction: AIRE Extension (AIREX) Study. Acute Infarction Ramipril Efficacy [see comments]. *Lancet* 1997;349:1493-1497.
- Hansson L, Lindholm L, Niskanen L, et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: The Captopril Prevention Project (CAPPP) randomised trial. *Lancet* 1999;353:611-616.
- Harrap SB. Hypertension: Genes versus environment. *Lancet* 1994;344:169-171.
- Heeg JE, de Jong PE, van der Hem GK, et al. Efficacy and variability of the antiproteinuric effect of ACE inhibition by lisinopril. *Kidney Int* 1989;36:272-279.
- Herings RMC, de Boer A, Stricker BHCH, et al. Hypoglycemia associated with use of inhibitors of angiotensin converting enzyme. *Lancet* 1995;345:1194-1198.
- Herrick AL, Waller PC, Berkin KE, et al. Comparison of enalapril and atenolol in mild to moderate hypertension. *Am J Med* 1989;86(4):421-426.
- Hilleman DE, Mohiuddin SM, Lucas BD Jr, Stading JA, Stoylich AM, Ryschon K. Cost-minimization analysis of initial antihypertensive therapy in patients with mild-to-moderate essential diastolic hypertension. *Clin Ther* 1994;16(1):88-102; discussion: 87.
- Hirakata H, Onoyama K, Iseki K, et al. Worsening of anemia by long-term use of captopril in hemodialysis patients. *Am J Nephrol* 1984;4:355-360.
- Hodsman GP, Isles CG, Murray GD, et al. Factors related to the first dose hypotensive effect of captopril: Prediction and treatment. *Br Med J* 1983;286:832-834.
- Hollenberg NK, Raij L. Angiotensin-converting enzyme inhibition and renal protection. An assessment of implications for therapy. *Arch Intern Med* 1993;153(21):2426-2435.
- Hoyer J, Schulte K-L, Lenz T. Clinical pharmacokinetics of angiotensin converting enzyme inhibitors in renal failure. *Clin Pharmacokinet* 1993;24:230-254.
- Israili ZH, Hall WD. ACEIs: Differential use in elderly patients with hypertension. *Drugs Aging* 1995;7:355-371.
- Israili ZH, Hall WD. Cough and angioneurotic edema associated with angiotensin converting enzyme inhibitor therapy. A review of the literature and pathophysiology. *Ann Intern Med* 1992;117:234-242.
- Jackson G. ATLAS: High dose lisinopril is superior to low dose in heart failure [editorial]. *Int J Clin Pract* 1998;52(3):139.
- Jacobs RP. Hypertension and managed care. *Am J Manag Care* 1998;4(suppl 12): S749-S752; discussion: S753-S756.
- Johannesson M. The cost-effectiveness of hypertension treatment in Sweden: An analysis of the criteria for intervention and the choice of drug treatment. *J Hum Hypertens* 1996;10(suppl 2):S23-S26.
- Johnston C, Risvanis J. Preclinical pharmacology of angiotensin II receptor antagonists: Update and outstanding issues. *Am J Hypertens* 1997;10(suppl):306S-310S.
- Johnston D, Duffin D. Drug-patient interactions and their relevance in the treatment of heart failure. *Am J Cardiol* 1992;70(10):109C-112C.
- Juillerat L, Nussberger J, Menard J, et al. Determinants of angiotensin II generation during converting enzyme inhibition. *Hypertension* 1990;16:564-572.
- Julius S, Jamerson K, Mejia A, et al. The association of borderline hypertension with target organ changes and higher coronary risk. Tecumseh Blood Pressure Study. *J Am Med Assoc* 1990;264:354-358.

... BIBLIOGRAPHY ...

- Kaplan NM. Primary hypertension: Pathogenesis. In: Kaplan NM, ed. *Clinical Hypertension* 7th ed. Baltimore, MD: Williams & Wilkins;1998:41-99.
- Kaplan NM. Treatment of hypertension: Drug therapy. In: Kaplan NM, ed. *Clinical Hypertension* 7th ed. Baltimore, MD: Williams & Wilkins;1998:181-263.
- Kasiske BL, Kalil RS, Ma JZ, Liao M, Keane WF. Effect of antihypertensive therapy on the kidney in patients with diabetes: A meta-regression analysis. *Ann Intern Med* 1993;118(2):129-138.
- Kawachi I, Malcolm LA. The benefits of treating mild to moderate hypertension. A quantitative estimation of the life expectancy gains from pharmacological reduction of blood pressure. *J Clin Epidemiol* 1989;42(9):905-912.
- Kawachi I, Malcolm LA. The cost-effectiveness of treating mild-to-moderate hypertension: A reappraisal. *J Hypertens* 1991;9(3):199-208.
- Koren MJ, Devereux RB, Casale PN, et al. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. *Ann Intern Med* 1991;114:345-352.
- Kozma CM, Reeder CE, Schulz RM. Economic, clinical, and humanistic outcomes: A planning model for pharmaco-economic research. *Clin Ther* 1993;15(6):1121-1132; discussion: 1120.
- Laffel LMB, McGill J, Gans D. The beneficial effects of angiotensin converting enzyme inhibition with captopril on diabetic nephropathy in normotensive IDDM patients with microalbuminuria. *Am J Med* 1995;99:497-503.
- Lang CC, Stein M, He HB, et al. Angiotensin converting enzyme inhibition and sympathetic activity in healthy subjects. *Clin Pharmacol Ther* 1996;59:668-674.
- Law CM, Shiell AW. Is blood pressure inversely related to birth weight? The strength of evidence from a systematic review of birth weight. *J Hypertens* 1996;14:935-941.
- Lebovitz HE, Wiegmann TB, Cnaan A, et al. Renal protective effect of enalapril in hypertensive NIDDM: Role of baseline albuminuria. *Kidney Int* 1994;45(suppl):S150-S155.
- Leonetti G, Cuspidi C. Choosing the right ACE inhibitor. A guide to selection. *Drugs* 1995;49(4):516-535.
- Levy D, Larson MG, Vasan RS, et al. The progression from hypertension to congestive heart failure. *JAMA* 1996;275:1557-1562.
- Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group [see comments] [published erratum appears in *N Engl J Med* 1993;330(2):152]. *N Engl J Med* 1993;329(20):1456-1462.
- Lithell HO, Pollare T, Berne C. Insulin sensitivity in newly detected hypertensive patients: Influence of captopril and other antihypertensive agents on insulin sensitivity and related biological parameters. *J Cardiovasc Pharmacol* 1990;15(suppl 5):S46-S52.
- Littenberg B, Garber AM, Sox HC Jr. Screening for hypertension [see comments]. *Ann Intern Med* 1990;112(3):192-202.
- Lonn EM, Yusuf S, Jha P, et al. Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection. *Circulation* 1994;90:2056-2069.
- Lüscher TF, Barton M. Biology of the endothelium. *Clin Cardiol* 1997;20(suppl II):II-3-II-10.
- Magrini F, Shimizu M, Roberts N, et al. Converting-enzyme inhibition and coronary blood flow. *Circulation* 1987;75:1168-1174.
- Malini P, Stochi E, Ambosini E, et al. Long-term antihypertensive, metabolic and cellular effects of enalapril. *J Hypertens* 1984;2(suppl 2):101-105.
- Mancini GB, Henry G, Macaya C, et al. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing Endothelial Dysfunction) study. *Circulation* 1996;94:258-265.
- Marques-Vidal P, Tuomilehto J. Hypertension awareness, treatment and control in the community: Is the rule of "halves" still valid? *J Hum Hypertens* 1997;11:213-220.
- Maschio G, Alberti D, Janin G, et al. Effect of the angiotensin-converting enzyme inhibitor benazepril on the progression of chronic renal insufficiency. *N Engl J Med* 1996;334:939-945.
- Maschio G, Alberti D, Locatelli F, et al. Angiotensin-converting enzyme inhibitors and kidney protection: The AIPRI trial. The ACE Inhibition in Progressive Renal Insufficiency (AIPRI) Study Group. *J Cardiovasc Pharmacol* 1999;33(suppl 1):S16-S20; discussion: S41-S43.

... BIBLIOGRAPHY ...

- Materson BJ, Reda DJ, Cushman WC, et al. Single-drug therapy for hypertension in men. A comparison of six antihypertensives agents with placebo. *N Engl J Med* 1993;328:914-921.
- McCorvey E Jr, Wright JT Jr, Culbert JP, McKenney JM, Proctor JD, Annett MP. Effect of hydrochlorothiazide, enalapril, and propranolol on quality of life and cognitive and motor function in hypertensive patients. *Clin Pharm* 1993;12(4):300-305.
- McMurray JJ, McGuire A, Davie AP, Hughes D. Cost-effectiveness of different ACE inhibitor treatment scenarios post-myocardial infarction. *Eur Heart J* 1997;18(9):1411-1415.
- Megarry M, Sapsford R, Hall AS, et al. Do ACEIs provide protection for the heart in the clinical setting of acute myocardial infarction. *Drugs* 1997;54(suppl 5):48-58.
- Mignat C, Unger T. ACEIs. Drug interactions of clinical significance. *Drug Safety* 1995;12:334-347.
- Mooser V, Nussberger J, Juillerat L, et al. Reactive hyperreninemia is a major determinant of plasma angiotensin II during ACE inhibition. *J Cardiovasc Pharmacol* 1990;15:276-282.
- Morioka S, Simon G, Cohn JN. Cardiac and hormonal effects of enalapril in hypertension. *Clin Pharmacol Ther* 1988;34:583-589.
- Morrone LF, Di Paolo S, Logoluso F, et al. Interference of angiotensin-converting enzyme inhibitors on erythropoiesis on kidney transplant recipients: Role of growth factors and cytokines. *Transplantation* 1997;64:913-918.
- Muiesan G, Alicandri CL, Agabiti-Rosei E, et al. Angiotensin-converting enzyme inhibition, catecholamines, and hemodynamics in essential hypertension. *Am J Cardiol* 1980;46:1420-1424.
- Mulrow PJ. Hypertension: A worldwide epidemic. In: Izzo JL, Black HR, eds. *Hypertension Primer* 2nd ed. Baltimore, MD: Lippincott Williams & Wilkins;1999:271-273.
- National Heart, Lung, and Blood Institute staff. Calculated data. Cutler J, principal investigator. Bethesda, MD: National Heart, Lung, and Blood Institute; January 1997 (unpublished data).
- National Heart, Lung, and Blood Institute. *Fact Book Fiscal Year 1997* Bethesda, MD. US Department of Health and Human Services, National Institutes of Health;1998.
- National Heart, Lung, and Blood Institute. *Fact Book Fiscal Year 1996* Bethesda, MD: US Department of Health and Human Services, National Institutes of Health, 1997.
- Navis G, de Jong PE, de Zeeuw D. Optimizing the renal response to ACE inhibition: A strategy toward more effective long-term renoprotection. *Adv Nephrol* 1998;27:57-66.
- Navis G, Faber HJ, de Zeeuw D, de Jong PE. ACEIs and the kidney. *Drug Safety* 1996;15:200-211.
- Nawarskas JJ, Spinler SA. Does aspirin interfere with the therapeutic efficacy of angiotensin-converting enzyme inhibitors in hypertension or congestive heart failure. *Pharmacotherapy* 1998;18:1041-1052.
- Nielsen FS, Sato A, Ali S, et al. Beneficial impact of ramipril on left ventricular hypertrophy in normotensive nonalbuminuric NIDDM patients [see comments]. *Diabetes Care* 1998;21(5):804-809.
- Nussberger J, Brunner DB, Waeber A, et al. Lack of angiotensin I accumulation after converting enzyme blockade with enalapril or lisinopril in man. *Clin Sci* 1987;72:387-389.
- Ogihara T, Maruyama A, Hata T, et al. Hormonal responses to long-term converting enzyme inhibition in hypertensive patients. *Clin Pharmacol Ther* 1981;30:328-335.
- Oldenburg B, MacDonald GJ, Shelley S. Controlled trial of enalapril in patients with chronic fluid overload undergoing dialysis. *Br Med J* 1988;296:1089-1091.
- Omboni S, Fogari R, Palatini P, et al. Reproducibility and clinical value of the trough-to-peak ratio of the antihypertensive effect. Evidence from the Sample Study. *Hypertension* 1998;32:424-429.
- Omboni S, Parati G, Zanchetti A, Mancia G. Calculation of trough: peak ratio of antihypertensive treatment from ambulatory blood pressure: Methodologic aspects. *J Hypertens* 1995;13:1105-1112.
- Omvik P, Lund-Johansen P. Combined captopril and hydrochlorothiazide therapy in severe hypertension: Long-term haemodynamic changes at rest and during exercise. *J Hypertens* 1984;2:73-80.

... BIBLIOGRAPHY ...

- Parmley WW. Cost-effective management of heart failure. *Clin Cardiol* 1996;19(3):240-242.
- Parving HH, Jacobsen P, Tarnow L, et al. Effect of deletion polymorphism of angiotensin converting enzyme gene on progression of diabetic nephropathy during inhibition of angiotensin converting enzyme. Observational follow-up study. *Br Med J* 1996;313:591-594.
- Paul M, Bachmann J, Ganten D. The tissue renin-angiotensin system in cardiovascular disease. *Trends Cardiovasc Med* 1992;2:94-99.
- Peters H, Border WA, Noble NA. Targeting TGF- β over-expression in renal disease: Maximizing the antifibrotic action of angiotensin II blockade. *Kidney Int* 1998;54:1570-1580.
- Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators [see comments]. *N Engl J Med* 1992;327(10):669-677.
- Philbin EF, Andreou C, Rocco TA, Lynch LJ, Baker SL. Patterns of angiotensin-converting enzyme inhibitor use in congestive heart failure in two community hospitals. *Am J Cardiol* 1996;77:832-838.
- Preston RA. Renoprotective effects of antihypertensive drugs. *Am J Hypertens* 1999;12(suppl):19S-32S.
- Program NHBPE. The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Bethesda, MD: National Institutes of Health, 1997.
- Pryde PG, Sedman AB, Nugent CE, et al. Angiotensin-converting enzyme fetopathy. *J Am Soc Nephrol* 1993;3:1575-1582.
- Punzi HD. Safety update: Focus on cough. *Am J Cardiol* 1993;72:45H-48H.
- Ravid M, Lang R, Rachmani R, et al. Long-term renoprotective effect of angiotensin converting enzyme inhibition in non-insulin dependent diabetes mellitus. A 7-year follow-up study. *Arch Intern Med* 1996;156:286-289.
- Rector TS, Johnson G, Dunkman WB, et al. Evaluation by patients with heart failure of the effects of enalapril compared with hydralazine plus isosorbide dinitrate on quality of life. V-HeFT II. The V-HeFT VA Cooperative Studies Group. *Circulation* 1993;87(suppl 6):VI71-77.
- Remme WJ. Effect of ACE inhibition on neurohormones. *Eur Heart J* 1998;19(suppl J):J16-J23.
- Rich MW, Nease RF. Cost-effectiveness analysis in clinical practice: The case of heart failure. *Arch Intern Med* 1999;159(15):1690-1700.
- Rigat B, Hubert C, Alhenc-Gelas F, et al. An insertion/deletion polymorphism in the angiotensin I converting enzyme gene accounting for half the variance of serum enzyme levels. *J Clin Invest* 1990;86:1343-1346.
- Ripley E, Sica DA. Hypertension. In: Hess M, ed. *Heart Disease in Primary Care* 1st ed. Baltimore, MD: Lippincott Williams & Wilkins;1999:78-104.
- Roberts DH, Tsao Y, McLoughlin GA, et al. Placebo-controlled comparison of captopril, atenolol, labetalol, and pindolol in hypertension complicated by intermittent claudication. *Lancet* 1987;2:650-653.
- Rosendorff C. The renin-angiotensin system and vascular hypertrophy. *J Am Coll Cardiol* 1996;28:803-812.
- Ruddy MC, Kostis JB, Frishman WH. Drugs that affect the renin-angiotensin system. In: Frishman WH, Sonnenblick EH, eds. *Cardiovascular Pharmacotherapeutics* New York; McGraw-Hill;1997:131-192.
- Ryan TJ, Antman EM, Brooks NH, et al. 1999 update: ACC/AHA Guidelines for the Management of Patients With Acute Myocardial Infarction: Executive Summary and Recommendations: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). *Circulation* 1999;100(9):1016-1030.
- Salvetti A, Abdel-Hag B, Magagna A, et al. Indomethacin reduces the antihypertensive effect of enalapril. *Clin Exp Hypertens* 1987;9:559-567.
- Salvetti A. Newer ACEIs: A look at the future. *Drugs* 1990;40:800-828.
- Samanta A, Burden AC. Fever, myalgia, and arthralgia in a patient on captopril and allopurinol. *Lancet* 1984;1:679.
- Saragoca MA, Homsy E, Ribeiro AB, et al. Hemodynamic mechanism of blood pressure response to captopril in human malignant hypertension. *Hypertension* 1983;5(suppl 1):53-59.
- Schlaich MP, Schmieder RE. Left ventricular hypertrophy and its regression: Pathophysiology and therapeutic approach. *Am J Hypertens* 1998;11:1394-1404.

... BIBLIOGRAPHY ...

- Shepard DS, Hodgkin D. Cost effectiveness of intensive treatment of hypertension *Am J Manag Care* 1998;4(suppl 12):S765-S769; discussion: S770.
- Shulman NB. Economic issues relating to access to medications. *Cardiovasc Clin* 1991;21(3):75-82.
- Sica DA, Cutler RE, Parmer RJ, et al. Comparison of the steady-state pharmacokinetics of fosinopril, lisinopril, and enalapril in patients with chronic renal insufficiency. *Clin Pharmacokinet* 1991;20:420-427.
- Sica DA, Deedwania PC. Renal considerations in the use of angiotensin-converting enzyme inhibitors in the treatment of congestive heart failure. *Congestive Heart Failure* 1997;3:54-59.
- Sica DA, Gehr TWB. Dose-response relationship and dose adjustments. In: Izzo JL, Black HR, eds. *Hypertension Primer* 2nd ed. Baltimore, MD: Lippincott, Williams & Wilkins;1999:342-344.
- Sica DA, Ripley E. Angiotensin converting enzyme inhibitors. In: Izzo JL, Black HR, eds. *Hypertension Primer* 2nd ed. Baltimore, MD: Lippincott Williams & Wilkins;1999:372-376.
- Sica DA. Fixed-dose combination antihypertensive drugs. Do they have a role in rational therapy? *Drugs* 1994;48:16-24.
- Sica DA. Antihypertensive therapy. In: Izzo JL, Black HR, eds. *Hypertension Primer* 2nd ed. Baltimore, MD: Lippincott Williams & Wilkins;1999:358-389.
- Sica DA. Kinetics of angiotensin converting enzyme inhibitors in renal failure. *J Cardiovasc Pharmacol* 1992;20(suppl 10):S13-S20.
- Sica DA. Mechanisms of hypertension. Opportunities to individualize on the basis of pathophysiology and pharmacokinetics. *Postgrad Med J* 1998;October:5-10.
- Siegel D, Lopez J, Meier J. Pharmacologic treatment of hypertension in the Department of Veterans Affairs during 1995 and 1996. *Am J Hypertens* 1998;11:1271-1278.
- Skaer TL, Sclar DA, Robison LM. Noncompliance with antihypertensive therapy. Economic consequences. *Pharmacoeconomics* 1996;9(1):1-4.
- Smith RD, Franklin SS. Comparison of effects of enalapril plus hydrochlorothiazide versus standard triple therapy on renal function in renovascular hypertension. *Am J Med* 1985;79(suppl 3C):14-23.
- Stafford RS, Saglam D, Blumenthal D. National patterns of angiotensin-converting enzyme inhibitor use in congestive heart failure. *Arch Intern Med* 1997;157:2460-2464.
- Stamler J. Blood pressure and high blood pressure. Aspects of risk. *Hypertension* 1991;18(suppl 3):95-107.
- Stason WB, Weinstein MC. Public-health rounds at the Harvard School of Public Health. Allocation of resources to manage hypertension. *N Engl J Med* 1977;296(13):732-739.
- Stevens RD, Bingley LJ Jr, Boger M, El-Wanni J, Kaston J. Variability in the management of hypertension and cost-effectiveness: Methodology, community care results and potential cost reductions. *Soc Sci Med* 1984;18(9):767-774.
- Swedberg K, Eneroth P, Kjekshus J, Wilhelmsen L. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group. *Circulation* 1990;82:1730-1736.
- Swedberg K, Kjekshus J, Snapinn S. Long-term survival in severe heart failure in patients treated with enalapril. Ten year follow-up of CONSENSUS I [see comments]. *Eur Heart J* 1999;20(2):136-139.
- Szucs TD. Pharmacoeconomics of angiotensin converting enzyme inhibitors in heart failure. *Am J Hypertens* 1997;10(10 Pt 2):272S-279S.
- Testa MA, Anderson RB, Nackley JF, Hollenberg NK. Quality of life and antihypertensive therapy in men. A comparison of captopril with enalapril. The Quality-of-Life Hypertension Study Group [see comments]. *N Engl J Med* 1993;328(13):907-913.
- Textor S, Bravo EL, Fouad FM, et al. Hyperkalemia in azotemic patients during angiotensin converting enzyme inhibition and aldosterone reduction with captopril. *Am J Med* 1982;73:719-725.
- Textor SC. Renal failure related to angiotensin-converting enzyme inhibitors. *Semin Nephrol* 1997;17:67-76.
- The American College of Cardiology/American Heart Association Task Force on Practical Guidelines (Committee on Evaluation and Management of Heart Failure). Guidelines for the evaluation and management of heart failure. *Circulation* 1995;92:2764-2784.

... BIBLIOGRAPHY ...

- The ATLAS Investigators. Comparative effects of low-dose versus high-dose lisinopril on survival and major cardiac events in chronic heart failure. *Eur Heart J* 1998;19:142 [Abstract].
- The Gisen Group. Randomized placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. *Lancet* 1997;349:1857-1863.
- The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. *Arch Intern Med* 1997;157:2413-2446.
- The SOLVD investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. *N Engl J Med* 1991;325:293-302.
- Thervet E, Legendre C, Debure A, et al. Angiotensin-converting enzyme inhibitors have been reported to induce or worsen anemia in patients on hemodialysis (letter). *Am J Kidney Dis* 1991;18:282-283.
- Tillmann HC, Walker RJ, Lewis-Barned NJ, et al. A long-term comparison between enalapril and captopril on insulin sensitivity in normotensive non-insulin dependent diabetic volunteers. *J Clin Pharmacol Ther* 1997;22:273-278.
- Toto RD, Mitchell HC, Lee HC, et al. Reversible renal insufficiency due to angiotensin converting enzyme inhibitors in hypertensive nephrosclerosis. *Ann Intern Med* 1991;115:513-519.
- Tsevat J, Duke D, Goldman L, et al. Cost-effectiveness of captopril therapy after myocardial infarction [see comments]. *J Am Coll Cardiol* 1995;26(4):914-919.
- Ueda S, Elliott HL, Morton JJ, et al. Enhanced pressor response to angiotensin I in normotensive men with the deletion genotype (DD) for angiotensin-converting enzyme. *Hypertension* 1995;25:1266-1269.
- Uhle BU, Whitworth JA, Shahinfar S, et al. Angiotensin-converting enzyme inhibition in nondiabetic progressive renal insufficiency: A controlled double-blind trial. *Am J Kidney Dis* 1996;27:489-495.
- UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in Type II diabetes. *Br Med J* 1998;317:713-720.
- Urata H, Nishimura H, Ganten D. Chymase-dependent angiotensin II forming system in humans. *Amer J Hypertens* 1996;9:277-284.
- US Renal Data System. *USRDS 1998 Annual Report* Bethesda, MD: US Dept of Health and Human Services, National Institutes of Diabetes and Digestive Diseases;1998.
- van Essen GG, Rensma PL, de Zeeuw D, et al. Association between angiotensin converting enzyme gene polymorphism and failure of renoprotective therapy. *Lancet* 1996;347:94-95.
- Van Veldhuisen DJ, Genth-Zotz S, Brouwer J, et al. High versus low-dose ACE inhibition in chronic heart failure. A double-blind, placebo-controlled study of imidapril. *J Am Coll Cardiol* 1998;32:1811-1818.
- Vander AJ, Geelhoed GW. Inhibition of renin secretion by angiotensin II. *Proc Soc Exp Biol Med* 1965;120:399-403.
- Vanhoutte PM. Endothelial dysfunction and inhibition of converting enzyme. *Eur Heart J* 1998;19(suppl J):J7-J15.
- Vertes V, Haynie R. Comparative pharmacokinetics of captopril, enalapril, and quinapril. *Am J Cardiol* 1992;69(10):8C-16C.
- Vleeming W, van Amsterdam JGC, Stricker BH, et al. ACE-inhibitor induced angioedema. *Drug Safety* 1998;18:171-188.
- Waeber B, Nussberger J, Brunner HR. Angiotensin-converting enzyme inhibitors in hypertension. In: Laragh JH, Brenner BM, eds. *Hypertension: Pathophysiology, Diagnosis, and Management* 2nd ed. New York: Raven Press, Ltd.:2861-2875.
- Waldemar G, Ibsen H, Strandgaard S, et al. The effect of fosinopril sodium on cerebral blood flow in moderate essential hypertension. *Am J Hypertens* 1990;3:464-470.
- Webster J, Koch HF. Aspects of tolerability of centrally acting antihypertensive drugs. *J Cardiovasc Pharmacol* 1996;27(suppl):S49-S54.
- Weidmann P, De Myttenaere-Bursztejn S, Maxwell MH. Effect of aging on plasma renin and aldosterone in normal man. *Kidney Int* 1975;8:325-333.

... BIBLIOGRAPHY ...

- Weinberger MH. Blood pressure and metabolic responses to hydrochlorothiazide, captopril, and the combination in black and white mild-to-moderate hypertensive patients. *J Cardiovasc Pharmacol* 1985;7(suppl 1):52-55.
- Weinberger MH. Influence of an angiotensin-converting enzyme inhibitor on diuretic-induced metabolic effects in hypertension. *Hypertension* 1983;5(suppl III):132-138.
- Weinstein MC, Coxson PG, Williams LW, Pass TM, Stason WB, Goldman L. Forecasting coronary heart disease incidence, mortality, and cost: The Coronary Heart Disease Policy Model. *Am J Public Health* 1987;77(11):1417-1426.
- Weir MR, Gray JM, Paster R, et al. Differing mechanisms of action of angiotensin-converting enzyme inhibition in black and white hypertensive patients. *Hypertension* 1995;26:124-130.
- White CM. Pharmacologic, pharmacokinetic, and therapeutic differences among ACE inhibitors. *Pharmacotherapy* 1998;18(3):588-599.
- Wiklund J, Halling K, Ryden-Bergsten T, Fletcher A, on behalf of the HOT Study Group. Does lowering the blood pressure improve the mood: Quality of life results from the Hypertension Optimal Treatment (HOT) Study. *Blood Pressure* 1997;6:357-364.
- Williams GH. Converting-enzyme inhibitors in the treatment of hypertension. *N Engl J Med* 1988;319(23):1517-1525.
- Wolfel EE. Effects of ACE inhibitor therapy on quality of life in patients with heart failure. *Pharmacotherapy* 1998;18(6):1323-1334.
- Yusuf S, Lonn E. Anti-ischemic effects of ACEIs: Review of current clinical evidence and ongoing clinical trials. *Eur Heart J* 1998;19(suppl J):J36-J44.
- Zannad F. Trandolapril. How does it differ from other angiotensin converting enzyme inhibitors? *Drugs* 1993;46(suppl 2):172-1781; discussion: 182.
- Zusman RM. Angiotensin-converting enzyme inhibitors: More different than alike? *Am J Cardiol* 1993;72:25H-36H.
- Zusman RM. Effects of converting-enzyme inhibitors on the renin-angiotensin-aldosterone, bradykinin, and arachidonic acid-prostaglandin systems: Correlation of chemical structure and biological activity. *Am J Kidney Dis* 1987;10(suppl 1):13-23.